Physician profile
Beverly E Summer
NPI 1982767497
$296.30
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $296.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $72.30 | 2022 | |
| Mylan Pharmaceuticals INC. | $32.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.16 | 2022 | |
| Exeltis, USA INC. | $29.00 | 2022 | |
| Daiichi Sankyo INC. | $20.65 | 2022 | |
| Aspira Women'S Health INC | $20.43 | 2022 | |
| Pfizer INC. | $18.01 | 2022 | |
| Urovant Sciences INC | $17.88 | 2022 | |
| Therapeuticsmd, INC. | $16.13 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.37 | 2022 | |
| Scynexis, INC. | $12.99 | 2022 | |
| Evofem Biosciences, INC. | $12.51 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Summer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.